Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms.

Lee J, Minden MD, Chen WC, Streck E, Chen B, Kang H, Arruda A, Ly D, Der SD, Kang S, Achita P, D'Souza C, Li Y, Childs RW, Dick JE, Zhang L.

Clin Cancer Res. 2018 Jan 15;24(2):370-382. doi: 10.1158/1078-0432.CCR-17-2228. Epub 2017 Oct 26.

PMID:
29074605
2.

Essential Medications for Patients With Suspected or Confirmed Ebola Virus Disease in Resource-Limited Environments.

Pierce WF, Ready SD, Chapman JT, Kulick C, Shields A, Wang J, Andrews K, Childs RW, Bell C, Kosyak A, Pham J.

Mil Med. 2017 Sep;182(9):e2006-e2016. doi: 10.7205/MILMED-D-17-00010.

PMID:
28885970
3.

Transcriptome analysis reveals similarities between human blood CD3- CD56bright cells and mouse CD127+ innate lymphoid cells.

Allan DSJ, Cerdeira AS, Ranjan A, Kirkham CL, Aguilar OA, Tanaka M, Childs RW, Dunbar CE, Strominger JL, Kopcow HD, Carlyle JR.

Sci Rep. 2017 Jun 14;7(1):3501. doi: 10.1038/s41598-017-03256-0.

4.

Allogeneic transplantation using CD34+ selected peripheral blood progenitor cells combined with non-mobilized donor T cells for refractory severe aplastic anaemia.

Purev E, Tian X, Aue G, Pantin J, Vo P, Shalabi R, Reger RN, Cook L, Ramos C, Cho E, Worthy T, Khuu H, Stroncek D, Young NS, Childs RW.

Br J Haematol. 2017 Mar;176(6):950-960. doi: 10.1111/bjh.14448. Epub 2017 Feb 7.

PMID:
28169418
5.

Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation.

McDuffee E, Aue G, Cook L, Ramos-Delgado C, Shalabi R, Worthy T, Vo P, Childs RW.

Bone Marrow Transplant. 2017 May;52(5):759-761. doi: 10.1038/bmt.2016.346. Epub 2017 Jan 9. No abstract available.

PMID:
28067871
6.

Early Diagnosis of Labial Fusion in Women After Allogeneic Hematopoietic Cell Transplant Enables Outpatient Treatment.

Scrivani C, Merideth MA, Klepac Pulanic T, Pavletic S, Childs RW, Hsieh MM, Stratton P.

J Low Genit Tract Dis. 2017 Apr;21(2):157-160. doi: 10.1097/LGT.0000000000000288.

7.

Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial.

Pantin J, Purev E, Tian X, Cook L, Donohue-Jerussi T, Cho E, Reger R, Hsieh M, Khuu H, Calandra G, Geller NL, Childs RW.

Haematologica. 2017 Mar;102(3):600-609. doi: 10.3324/haematol.2016.147132. Epub 2016 Oct 20.

8.

Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma.

Carlsten M, Korde N, Kotecha R, Reger R, Bor S, Kazandjian D, Landgren O, Childs RW.

Clin Cancer Res. 2016 Nov 1;22(21):5211-5222. Epub 2016 Jun 15.

9.

Cardiac MRI Findings Suggest Myocarditis in Severe Ebola Virus Disease.

Chertow DS, Childs RW, Arai AE, Davey RT Jr.

JACC Cardiovasc Imaging. 2017 Jun;10(6):711-713. doi: 10.1016/j.jcmg.2016.06.004. Epub 2016 Aug 17. No abstract available.

PMID:
27544899
10.

mRNA Transfection to Improve NK Cell Homing to Tumors.

Levy ER, Carlsten M, Childs RW.

Methods Mol Biol. 2016;1441:231-40. doi: 10.1007/978-1-4939-3684-7_19.

PMID:
27177670
11.

Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19.

Carlsten M, Levy E, Karambelkar A, Li L, Reger R, Berg M, Peshwa MV, Childs RW.

Front Immunol. 2016 Mar 22;7:105. doi: 10.3389/fimmu.2016.00105. eCollection 2016.

12.

Severe Meningoencephalitis in a Case of Ebola Virus Disease: A Case Report.

Chertow DS, Nath A, Suffredini AF, Danner RL, Reich DS, Bishop RJ, Childs RW, Arai AE, Palmore TN, Lane HC, Fauci AS, Davey RT.

Ann Intern Med. 2016 Aug 16;165(4):301-4. doi: 10.7326/M15-3066. Epub 2016 Apr 5. No abstract available.

13.

Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer.

Cherkasova E, Scrivani C, Doh S, Weisman Q, Takahashi Y, Harashima N, Yokoyama H, Srinivasan R, Linehan WM, Lerman MI, Childs RW.

Cancer Res. 2016 Apr 15;76(8):2177-85. doi: 10.1158/0008-5472.CAN-15-3139. Epub 2016 Feb 9.

14.

Divalent cation-responsive myotonia and muscle paralysis in skeletal muscle sodium channelopathy.

Mankodi A, Grunseich C, Skov M, Cook L, Aue G, Purev E, Bakar D, Lehky T, Jurkat-Rott K, Pedersen TH, Childs RW.

Neuromuscul Disord. 2015 Nov;25(11):908-12. doi: 10.1016/j.nmd.2015.08.007. Epub 2015 Aug 20.

15.

A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation.

Vasu S, Berg M, Davidson-Moncada J, Tian X, Cullis H, Childs RW.

Cytotherapy. 2015 Nov;17(11):1582-93. doi: 10.1016/j.jcyt.2015.07.020.

PMID:
26432560
16.

Human hematopoietic stem cells from mobilized peripheral blood can be purified based on CD49f integrin expression.

Huntsman HD, Bat T, Cheng H, Cash A, Cheruku PS, Fu JF, Keyvanfar K, Childs RW, Dunbar CE, Larochelle A.

Blood. 2015 Sep 24;126(13):1631-3. doi: 10.1182/blood-2015-07-660670. No abstract available.

17.

Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications.

Carlsten M, Childs RW.

Front Immunol. 2015 Jun 10;6:266. doi: 10.3389/fimmu.2015.00266. eCollection 2015. Review.

18.

Conditioning with rabbit versus horse ATG dramatically alters clinical outcomes in identical twins with severe aplastic anemia transplanted with the same allogeneic donor.

Vo PT, Pantin J, Ramos C, Cook L, Cho E, Kurlander R, Khuu H, Barrett J, Leitman S, Childs RW.

J Hematol Oncol. 2015 Jun 26;8:78. doi: 10.1186/s13045-015-0173-x.

19.

Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

Childs RW, Carlsten M.

Nat Rev Drug Discov. 2015 Jul;14(7):487-98. doi: 10.1038/nrd4506. Epub 2015 May 22. Review.

PMID:
26000725
20.

Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy.

Granzin M, Soltenborn S, Müller S, Kollet J, Berg M, Cerwenka A, Childs RW, Huppert V.

Cytotherapy. 2015 May;17(5):621-32. doi: 10.1016/j.jcyt.2015.03.611.

21.

Optimization of intrabone delivery of hematopoietic progenitor cells in a swine model using cell radiolabeling with [89]zirconium.

Pantin JM, Hoyt RF Jr, Aras O, Sato N, Chen MY, Hunt T, Clevenger R, Eclarinal P, Adler S, Choyke P, Childs RW.

Am J Transplant. 2015 Mar;15(3):606-17. doi: 10.1111/ajt.13007. Epub 2015 Feb 5.

22.

Engraftment of donor cells with germ-line integration of HHV6 mimics HHV6 reactivation following cord blood/haplo transplantation.

Purev E, Winkler T, Danner RL, Fahle GA, Cook L, Zerr DM, Jerome KR, Childs RW.

Blood. 2014 Aug 14;124(7):1198-9. doi: 10.1182/blood-2014-06-577684. No abstract available.

23.

Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria.

Pantin J, Tian X, Geller N, Ramos C, Cook L, Cho E, Scheinberg P, Vasu S, Khuu H, Stroncek D, Barrett J, Young NS, Donohue T, Childs RW.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1435-9. doi: 10.1016/j.bbmt.2014.05.012. Epub 2014 May 17.

24.

Persistence of recipient human leucocyte antigen (HLA) antibodies and production of donor HLA antibodies following reduced intensity allogeneic haematopoietic stem cell transplantation.

Fasano RM, Mamcarz E, Adams S, Donohue Jerussi T, Sugimoto K, Tian X, Flegel WA, Childs RW.

Br J Haematol. 2014 Aug;166(3):425-34. doi: 10.1111/bjh.12890. Epub 2014 Apr 18.

25.

Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation.

Elinoff JM, Bagci U, Moriyama B, Dreiling JL, Foster B, Gormley NJ, Salit RB, Cai R, Sun J, Beri A, Reda DJ, Fakhrejahani F, Battiwalla M, Baird K, Cuellar-Rodriguez JM, Kang EM, Pavletic SZ, Fowler DH, John Barrett A, Lozier JN, Kleiner DE Jr, Mollura DJ, Childs RW, Suffredini AF.

Biol Blood Marrow Transplant. 2014 Jul;20(7):969-78. doi: 10.1016/j.bbmt.2014.03.015. Epub 2014 Mar 20.

26.

Bringing natural killer cells to the clinic: ex vivo manipulation.

Childs RW, Berg M.

Hematology Am Soc Hematol Educ Program. 2013;2013:234-46. doi: 10.1182/asheducation-2013.1.234. Review.

PMID:
24319186
27.

Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF.

Lundqvist A, Smith AL, Takahashi Y, Wong S, Bahceci E, Cook L, Ramos C, Tawab A, McCoy JP Jr, Read EJ, Khuu HM, Bolan CD, Joo J, Geller N, Leitman SF, Calandra G, Dunbar C, Kurlander R, Childs RW.

J Immunol. 2013 Dec 15;191(12):6241-9. doi: 10.4049/jimmunol.1301148. Epub 2013 Nov 15.

28.

Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors.

Cherkasova E, Weisman Q, Childs RW.

Front Oncol. 2013 Sep 17;3:243. doi: 10.3389/fonc.2013.00243. Review.

29.

Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes.

Pantin J, Tian X, Shah AA, Kurlander R, Ramos C, Cook L, Khuu H, Stroncek D, Leitman S, Barrett J, Donohue T, Young NS, Geller N, Childs RW.

Am J Hematol. 2013 Oct;88(10):874-82. doi: 10.1002/ajh.23526. Epub 2013 Sep 3.

30.

Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience.

Hale GA, Arora M, Ahn KW, He W, Camitta B, Bishop MR, Bitan M, Cairo MS, Chan K, Childs RW, Copelan E, Davies SM, Perez MA, Doyle JJ, Gale RP, Vicent MG, Horn BN, Hussein AA, Jodele S, Kamani NR, Kasow KA, Kletzel M, Lazarus HM, Lewis VA, Myers KC, Olsson R, Pulsipher M, Qayed M, Sanders JE, Shaw PJ, Soni S, Stiff PJ, Stadtmauer EA, Ueno NT, Wall DA, Grupp SA.

Bone Marrow Transplant. 2013 Aug;48(8):1056-64. doi: 10.1038/bmt.2012.284. Epub 2013 Feb 18.

31.

Topical tacrolimus with custom trays in the treatment of severe oral chronic graft-versus-host disease refractory to a potent topical steroid therapy: a case report.

Brown RS, Edwards D, Walsh-Chocolaad T, Childs RW.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Apr;115(4):e26-30. doi: 10.1016/j.oooo.2012.07.487. Epub 2012 Oct 24.

32.

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer.

Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P, Gattinoni L, Heath JR, Kalos M, Marincola FM, Miller JS, Mostoslavsky G, Powell DJ Jr, Rao M, Restifo NP, Rosenberg SA, O'Shea J, Melief CJ.

J Transl Med. 2012 Mar 15;10:48. doi: 10.1186/1479-5876-10-48.

33.

Blood consult: granulocyte transfusions to treat invasive aspergillosis in a patient with severe aplastic anemia awaiting mismatched hematopoietic progenitor cell transplantation.

O'Donghaile D, Childs RW, Leitman SF.

Blood. 2012 Feb 9;119(6):1353-5. doi: 10.1182/blood-2011-10-345751. Epub 2011 Nov 22. No abstract available.

34.
35.
36.

Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer.

Cherkasova E, Malinzak E, Rao S, Takahashi Y, Senchenko VN, Kudryavtseva AV, Nickerson ML, Merino M, Hong JA, Schrump DS, Srinivasan R, Linehan WM, Tian X, Lerman MI, Childs RW.

Oncogene. 2011 Nov 24;30(47):4697-706. doi: 10.1038/onc.2011.179. Epub 2011 May 23.

37.

Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy.

Merims S, Li X, Joe B, Dokouhaki P, Han M, Childs RW, Wang ZY, Gupta V, Minden MD, Zhang L.

Leukemia. 2011 Sep;25(9):1415-22. doi: 10.1038/leu.2011.99. Epub 2011 May 13.

38.

Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH.

Calattini S, Sereti I, Scheinberg P, Kimura H, Childs RW, Cohen JI.

Blood. 2010 Nov 25;116(22):4546-59. doi: 10.1182/blood-2010-05-285452. Epub 2010 Aug 10.

39.

Ex vivo expansion of retrovirally transduced primate CD34+ cells results in overrepresentation of clones with MDS1/EVI1 insertion sites in the myeloid lineage after transplantation.

Sellers S, Gomes TJ, Larochelle A, Lopez R, Adler R, Krouse A, Donahue RE, Childs RW, Dunbar CE.

Mol Ther. 2010 Sep;18(9):1633-9. doi: 10.1038/mt.2010.117. Epub 2010 Jun 22.

40.

Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.

Hsieh MM, Kang EM, Fitzhugh CD, Link MB, Bolan CD, Kurlander R, Childs RW, Rodgers GP, Powell JD, Tisdale JF.

N Engl J Med. 2009 Dec 10;361(24):2309-17. doi: 10.1056/NEJMoa0904971.

41.

High-dose chemotherapy with blood or bone marrow transplants for rhabdomyosarcoma.

Stiff PJ, Agovi MA, Antman KH, Blaise D, Camitta BM, Cairo MS, Childs RW, Edwards JR, Gale RP, Hale GA, Lazarus HM, Arora M.

Biol Blood Marrow Transplant. 2010 Apr;16(4):525-32. doi: 10.1016/j.bbmt.2009.11.020. Epub 2009 Dec 2.

42.

Targeted antagonism of CXCR4 mobilizes progenitor cells under investigation for cardiovascular disease.

Blum A, Childs RW, Smith A, Patibandla S, Zalos G, Samsel L, McCoy JP, Calandra G, Csako G, Cannon RO 3rd.

Cytotherapy. 2009;11(8):1016-9. doi: 10.3109/14653240903131640.

43.

Fusarium proliferatum soft tissue infection at the site of a puncture by a plant: recovery, isolation, and direct molecular identification.

Palmore TN, Shea YR, Childs RW, Sherry RM, Walsh TJ.

J Clin Microbiol. 2010 Jan;48(1):338-42. doi: 10.1128/JCM.01525-09. Epub 2009 Nov 18.

44.

Expanding multiviral reactive T cells from cord blood.

Childs RW, Zerbe CS.

Blood. 2009 Aug 27;114(9):1725-6. doi: 10.1182/blood-2009-06-224238.

45.

A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display.

Baskar S, Suschak JM, Samija I, Srinivasan R, Childs RW, Pavletic SZ, Bishop MR, Rader C.

Blood. 2009 Nov 12;114(20):4494-502. doi: 10.1182/blood-2009-05-222786. Epub 2009 Aug 10.

46.

Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation.

Cui K, Zang C, Roh TY, Schones DE, Childs RW, Peng W, Zhao K.

Cell Stem Cell. 2009 Jan 9;4(1):80-93. doi: 10.1016/j.stem.2008.11.011.

47.

Natural killer cell immunotherapy for cancer: a new hope.

Srivastava S, Lundqvist A, Childs RW.

Cytotherapy. 2008;10(8):775-83. doi: 10.1080/14653240802648181. Review.

PMID:
19089686
48.

Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population.

Vasu S, Leitman SF, Tisdale JF, Hsieh MM, Childs RW, Barrett AJ, Fowler DH, Bishop MR, Kang EM, Malech HL, Dunbar CE, Khuu HM, Wesley R, Yau YY, Bolan CD.

Blood. 2008 Sep 1;112(5):2092-100. doi: 10.1182/blood-2008-03-143677. Epub 2008 Jun 3.

49.

Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells.

Takahashi Y, Harashima N, Kajigaya S, Yokoyama H, Cherkasova E, McCoy JP, Hanada K, Mena O, Kurlander R, Tawab A, Srinivasan R, Lundqvist A, Malinzak E, Geller N, Lerman MI, Childs RW.

J Clin Invest. 2008 Mar;118(3):1099-109. doi: 10.1172/JCI34409. Erratum in: J Clin Invest. 2008 Apr;118(4):1584. Abdul, Tawab [corrected to Tawab, Abdul].

50.

Mitochondrial DNA sequence heterogeneity of single CD34+ cells after nonmyeloablative allogeneic stem cell transplantation.

Yao YG, Childs RW, Kajigaya S, McCoy JP Jr, Young NS.

Stem Cells. 2007 Oct;25(10):2670-6. Epub 2007 Jul 12.

Supplemental Content

Loading ...
Support Center